Stock CANF CAN-FITE BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N3008

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 16:00:00 2024-07-17 EDT 		5-day change 1st Jan Change
3.64 USD -0.55% Intraday chart for Can-Fite BioPharma Ltd. +15.19% +65.45%
07-01 Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson CI
06-28 Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 12.97 28.72 38.62 19.52 8.817 20.5 - -
Enterprise Value (EV) 1 12.97 28.72 19.48 19.52 8.817 20.5 20.5 20.5
P/E ratio -0.95 x -1.49 x -1.52 x -2.35 x -0.71 x - - -
Yield - - - - - - - -
Capitalization / Revenue 6.38 x 37.6 x 45.3 x 24.1 x 11.9 x 34.2 x 1.93 x 1.33 x
EV / Revenue 6.38 x 37.6 x 45.3 x 24.1 x 11.9 x 34.2 x 1.93 x 1.33 x
EV / EBITDA - - - - - - - -
EV / FCF - - - - - -2.23 x 1 x 1.01 x
FCF Yield - - - - - -44.9% 100% 98.7%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 119,656 463,769 815,746 815,746 1,224,837 1,656,728 - -
Reference price 2 0.3740 0.1990 0.1470 0.0840 0.0260 0.0450 0.0450 0.0450
Announcement Date 3/27/20 3/25/21 3/24/22 3/30/23 3/28/24 - - -
1ILS in Million2ILS
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2.032 0.763 0.853 0.81 0.743 0.6 10.6 15.4
EBITDA - - - - - - - -
EBIT 1 -12 -14.14 -12.84 -10.1 -8.195 -8.518 0.7057 5.752
Operating Margin -590.7% -1,853.08% -1,505.51% -1,246.42% -1,102.96% -1,419.72% 6.66% 37.35%
Earnings before Tax (EBT) 1 -9.587 -14.44 -12.62 -10.17 -7.634 -9.152 4.958 20.23
Net income 1 -9.587 -14.44 -12.62 -10.17 -7.634 -8.318 0.9057 5.952
Net margin -471.8% -1,892.92% -1,478.9% -1,255.93% -1,027.46% -1,386.39% 8.54% 38.65%
EPS 2 -0.3942 -0.1332 -0.0967 -0.0358 -0.0367 - - -
Free Cash Flow 1 - - - - - -9.205 20.52 20.23
FCF margin - - - - - -1,534.17% 193.56% 131.36%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - 2,265.39% 339.86%
Dividend per Share - - - - - - - -
Announcement Date 3/27/20 3/25/21 3/24/22 3/30/23 3/28/24 - - -
1USD in Million2ILS
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 0.251 0.204 0.205 0.204 0.204 0.197 0.196 0.196 0.196 0.155 0.15 0.15 0.15 0.15
EBITDA - - - - - - - - - - - - - -
EBIT 1 -3.51 -4.028 -2.37 -2.07 -2.573 -3.083 - -1.784 -1.865 -1.834 -2.008 -2.154 -2.396 -2.642
Operating Margin -1,398.41% -1,974.51% -1,156.1% -1,014.71% -1,261.27% -1,564.97% - -910.2% -951.53% -1,183.23% -1,339% -1,436.33% -1,597.67% -1,761.67%
Earnings before Tax (EBT) 1 -3.4 -4.118 -2.434 -2.191 -2.529 -3.019 - -1.67 -1.762 -1.652 -2.008 -2.154 -2.396 -2.592
Net income 1 -3.4 -4.118 -2.434 -2.191 -2.529 -3.019 - -1.67 -1.762 -1.652 -2.008 -2.154 -2.396 -2.592
Net margin -1,354.58% -2,018.63% -1,187.32% -1,074.02% -1,239.71% -1,532.49% - -852.04% -898.98% -1,065.81% -1,339% -1,436.33% -1,597.67% -1,728.33%
EPS 2 -0.0319 -0.0322 - - -0.0342 - - - - -0.0367 - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/26/21 3/24/22 5/26/22 8/25/22 11/25/22 3/30/23 6/1/23 8/31/23 11/30/23 3/28/24 - - - -
1USD in Million2ILS
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - 19.1 - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - - - -9.21 20.5 20.2
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - 0.01 - - - - -
Capex / Sales - - 1.29% - - - - -
Announcement Date 3/27/20 3/25/21 3/24/22 3/30/23 3/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Can-Fite BioPharma Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.045
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+8.54% 100B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+11.97% 43.89B
BIOGEN INC. Stock Biogen Inc.
-11.76% 33.24B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-12.20% 16.08B
INCYTE CORPORATION Stock Incyte Corporation
+4.00% 14.68B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-1.90% 12.87B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+178.17% 10.55B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.74% 9.12B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.54% 8.83B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. CANF Stock
  4. CANF Stock
  5. Financials Can-Fite BioPharma Ltd.